Connection
Jeffrey Bennett to Clinical Trials, Phase III as Topic
This is a "connection" page, showing publications Jeffrey Bennett has written about Clinical Trials, Phase III as Topic.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.069 |
|
|
|
-
St?ve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev. 2007; 13(1):79-95.
Score: 0.069